PMID- 31641796
OWN - NLM
STAT- MEDLINE
DCOM- 20191202
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 68
IP  - 12
DP  - 2019 Dec
TI  - Autophagy inhibition induces the repolarisation of tumour-associated macrophages 
      and enhances chemosensitivity of laryngeal cancer cells to cisplatin in mice.
PG  - 1909-1920
LID - 10.1007/s00262-019-02415-8 [doi]
AB  - Tumour-associated macrophages (TAMs) are the key components in the tumour 
      microenvironment. TAMs have two major subtypes, M1 and M2. M1 macrophages are 
      tumour inhibitory, while M2 macrophages are tumour promotive. Repolarising TAMs 
      from M2 to M1 is a promising strategy in cancer treatment. M1 and M2 macrophages 
      were generated from murine bone marrow-derived macrophages (BMDMs). We found that 
      chloroquine (CQ), an autophagy inhibitor, was able to repolarise M2 macrophages 
      to the anti-tumour M1 phenotype. The repolarised macrophages demonstrated higher 
      phagocytotic activity towards Hep-2 laryngeal tumour cells and re-sensitised 
      Hep-2 cells to cisplatin (CDDP) treatment in vitro. While CQ did not demonstrate 
      cytotoxicity to Hep-2 cells in vitro, CQ treatment reduced Hep-2 laryngeal tumour 
      growth in vivo and improved CDDP treatment outcomes. It seems that CQ-induced 
      M2-to-M1 macrophage repolarisation played an important role in tumour growth 
      inhibition, and the CQ/CDDP combined therapy might have clinical potential in 
      laryngeal cancer treatment.
FAU - Guo, Ying
AU  - Guo Y
AD  - Department of Otorhinolaryngology, Shandong Provincial Qianfoshan Hospital, 
      Shandong University, Jinan, 250014, Shandong, China.
FAU - Feng, Yufang
AU  - Feng Y
AD  - Department of Otorhinolaryngology, Weifang Yidu Central Hospital, Weifang, 
      262500, Shandong, China.
FAU - Cui, Xinhua
AU  - Cui X
AD  - Department of Otorhinolaryngology, Shandong Provincial Qianfoshan Hospital, 
      Shandong University, Jinan, 250014, Shandong, China.
FAU - Wang, Qirong
AU  - Wang Q
AD  - Department of Otorhinolaryngology, Shandong Provincial Qianfoshan Hospital, 
      Shandong University, Jinan, 250014, Shandong, China.
FAU - Pan, Xinliang
AU  - Pan X
AD  - Department of Otorhinolaryngology, Qilu Hospital, Shandong University, No. 107, 
      Wenhua West Road, Jinan, 250012, Shandong, China. panxinlent@163.com.
LA  - eng
GR  - 2017WSB04024/Project of Medical and Health Technology Development Program in 
      Shandong/
PT  - Journal Article
DEP - 20191022
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Cytokines)
RN  - 886U3H6UFF (Chloroquine)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Autophagy
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cell Transdifferentiation
MH  - Chloroquine/pharmacology
MH  - Cisplatin/*therapeutic use
MH  - Cytokines/metabolism
MH  - Drug Resistance, Neoplasm
MH  - Laryngeal Neoplasms/drug therapy/*immunology
MH  - Macrophages/*physiology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Nude
MH  - Th1 Cells/immunology
MH  - Th2 Cells/immunology
PMC - PMC11028258
OTO - NOTNLM
OT  - Autophagy inhibition
OT  - Chloroquine (CQ)
OT  - Hep-2 laryngeal cancer
OT  - Macrophage repolarisation
OT  - Tumour-associated macrophages (TAMs)
COIS- The authors declare that they have no conflict of interest.
EDAT- 2019/10/24 06:00
MHDA- 2019/12/04 06:00
PMCR- 2019/10/22
CRDT- 2019/10/24 06:00
PHST- 2019/04/01 00:00 [received]
PHST- 2019/10/10 00:00 [accepted]
PHST- 2019/10/24 06:00 [pubmed]
PHST- 2019/12/04 06:00 [medline]
PHST- 2019/10/24 06:00 [entrez]
PHST- 2019/10/22 00:00 [pmc-release]
AID - 10.1007/s00262-019-02415-8 [pii]
AID - 2415 [pii]
AID - 10.1007/s00262-019-02415-8 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2019 Dec;68(12):1909-1920. doi: 
      10.1007/s00262-019-02415-8. Epub 2019 Oct 22.